Hlb Pharmaceutical Co Stock Current Valuation
| 047920 Stock | KRW 23,400 700.00 2.90% |
Valuation analysis of HLB Pharmaceutical helps investors to measure HLB Pharmaceutical's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that HLB Pharmaceutical's price fluctuation is very steady at this time. Calculation of the real value of HLB Pharmaceutical is based on 3 months time horizon. Increasing HLB Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since HLB Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of HLB Stock. However, HLB Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 23400.0 | Real 19603.5 | Hype 24100.0 |
The real value of HLB Stock, also known as its intrinsic value, is the underlying worth of HLB Pharmaceutical Company, which is reflected in its stock price. It is based on HLB Pharmaceutical's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of HLB Pharmaceutical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of HLB Pharmaceutical Co helps investors to forecast how HLB stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of HLB Pharmaceutical more accurately as focusing exclusively on HLB Pharmaceutical's fundamentals will not take into account other important factors: HLB Pharmaceutical Co Company Current Valuation Analysis
HLB Pharmaceutical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current HLB Pharmaceutical Current Valuation | 216.14 B |
Most of HLB Pharmaceutical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HLB Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, HLB Pharmaceutical Co has a Current Valuation of 216.14 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Pharmaceuticals industry. The current valuation for all Republic of Korea stocks is significantly lower than that of the firm.
HLB Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HLB Pharmaceutical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HLB Pharmaceutical could also be used in its relative valuation, which is a method of valuing HLB Pharmaceutical by comparing valuation metrics of similar companies.HLB Pharmaceutical is currently under evaluation in current valuation category among its peers.
HLB Fundamentals
| Return On Equity | -11.39 | |||
| Return On Asset | 0.0219 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 216.14 B | |||
| Shares Outstanding | 13.85 M | |||
| Shares Owned By Insiders | 25.75 % | |||
| Shares Owned By Institutions | 0.13 % | |||
| Price To Sales | 5.60 X | |||
| Revenue | 62.85 B | |||
| Gross Profit | 18.04 B | |||
| EBITDA | 3.08 B | |||
| Net Income | (13.23 B) | |||
| Cash And Equivalents | 6.64 B | |||
| Total Debt | 2.14 B | |||
| Debt To Equity | 0.74 % | |||
| Current Ratio | 1.26 X | |||
| Cash Flow From Operations | (1.32 B) | |||
| Number Of Employees | 14 | |||
| Beta | 1.83 | |||
| Market Capitalization | 173.79 B | |||
| Total Asset | 127.63 B | |||
| Z Score | 48.6 | |||
| Net Asset | 127.63 B |
About HLB Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HLB Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HLB Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HLB Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with HLB Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLB Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLB Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving together with HLB Stock
Moving against HLB Stock
The ability to find closely correlated positions to HLB Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLB Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLB Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLB Pharmaceutical Co to buy it.
The correlation of HLB Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLB Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLB Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLB Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in HLB Stock
HLB Pharmaceutical financial ratios help investors to determine whether HLB Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLB with respect to the benefits of owning HLB Pharmaceutical security.